Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib

Balkan Med J. 2024 Jul 5;41(4):312-313. doi: 10.4274/balkanmedj.galenos.2024.2024-1-86. Epub 2024 Apr 4.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Guillain-Barre Syndrome* / drug therapy
  • Humans
  • Imidazoles* / adverse effects
  • Imidazoles* / therapeutic use
  • Melanoma / drug therapy
  • Middle Aged
  • Oximes* / adverse effects
  • Oximes* / therapeutic use
  • Pyridones* / adverse effects
  • Pyridones* / therapeutic use
  • Pyrimidinones* / adverse effects
  • Pyrimidinones* / therapeutic use

Substances

  • Antineoplastic Agents
  • dabrafenib
  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib